Cysteamine: an old drug with new potential

Hoagland, 1954, Biosynthesis of coenzyme A from phospho-pantetheine and of pantetheine from pantothenate, J. Biol. Chem., 207, 767, 10.1016/S0021-9258(18)65696-0

Coloso, 2006, Cysteamine dioxygenase: evidence for the physiological conversion of cysteamine to hypotaurine in rat and mouse tissues, Adv. Exp. Med. Biol., 583, 25, 10.1007/978-0-387-33504-9_3

Huxtable, 1992, Physiological actions of taurine, Physiol. Rev., 72, 101, 10.1152/physrev.1992.72.1.101

Ray, 2012, Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling, Cell. Signal., 24, 981, 10.1016/j.cellsig.2012.01.008

Trachootham, 2008, Redox regulation of cell survival, Antioxid. Redox Signal., 10, 1343, 10.1089/ars.2007.1957

Jeitner, 2001, Mechanisms for the cytotoxicity of cysteamine, Toxicol. Sci., 63, 57, 10.1093/toxsci/63.1.57

Smolin, 1988, A comparison of the effectiveness of cysteamine and phosphocysteamine in elevating plasma cysteamine concentration and decreasing leukocyte free cystine in nephropathic cystinosis, Pediatr. Res., 23, 616, 10.1203/00006450-198806000-00018

Dohil, 2012, The effect of food on cysteamine bitartrate absorption in healthy participants, Clin. Pharmacol. Drug Dev., 1, 170, 10.1177/2160763X12454423

Gangoiti, 2010, Pharmacokinetics of enteric-coated cysteamine bitartrate in healthy adults: a pilot study, Br. J. Clin. Pharmacol., 70, 376, 10.1111/j.1365-2125.2010.03721.x

Bacq, 1953, Protection against X-rays and therapy of radiation sickness with beta-mercaptoethylamine, Science, 117, 633, 10.1126/science.117.3049.633

Healy, 1960, A trial of cystamine in radiation sickness, Br. J. Radiol., 33, 512, 10.1259/0007-1285-33-392-512

Selye, 1973, Experimental model for production of perforating duodenal ulcers by cysteamine in the rat, Nature, 244, 458, 10.1038/244458a0

Szabo, 2007, New molecular mechanisms of duodenal ulceration, Ann. N. Y. Acad. Sci., 1113, 238, 10.1196/annals.1391.033

Fukuhara, 2005, Enhanced ghrelin secretion in rats with cysteamine-induced duodenal ulcers, Am. J. Physiol. Gastrointest. Liver Physiol., 289, G138, 10.1152/ajpgi.00298.2004

Szabo, 1981, Somatostatin in rat tissues is depleted by cysteamine administration, Endocrinology, 109, 2255, 10.1210/endo-109-6-2255

McLeod, 1995, Cysteamine-induced depletion of somatostatin in sheep: time course of depletion and changes in plasma metabolites, insulin, and growth hormone, J. Anim. Sci., 73, 77, 10.2527/1995.73177x

Yang, 2006, Effects of cysteamine on growth performance, digestive enzyme activities, and metabolic hormones in broilers, Poult. Sci., 85, 1912, 10.1093/ps/85.11.1912

Liu, 2008, Effects of dietary supplementation with cysteamine on growth hormone receptor and insulin-like growth factor system in finishing pigs, J. Agric. Food Chem., 56, 5422, 10.1021/jf800575p

Tse, 2006, Effects of chronic cysteamine treatment on growth enhancement and insulin-like growth factor I and II mRNA levels in common carp tissues, Br. J. Nutr., 96, 650

Hassan, 1976, Inhibition of erythrocyte sickling by cystamine, a thiol reagent, Proc. Natl. Acad. Sci. U. S. A., 73, 3288, 10.1073/pnas.73.9.3288

Ho, 1995, Cystamine inhibits HIV type 1 replication in cells of monocyte/macrophage and T cell lineages, AIDS Res. Hum. Retroviruses, 11, 451, 10.1089/aid.1995.11.451

Bryant, 1989, Cysteamine produces dose-related bidirectional immunomodulatory effects in mice, J. Pharmacol. Exp. Ther., 249, 424

Benke, 1990, Scavengers of free radical oxygen affect the generation of low molecular weight DNA in stimulated lymphocytes from patients with systemic lupus erythematosus, Metabolism, 39, 1278, 10.1016/0026-0495(90)90184-E

Brok, 2006, Interventions for paracetamol (acetaminophen) overdose, Cochrane Database Syst. Rev., 10.1002/14651858.CD003328.pub2

Gahl, 2002, Cystinosis, N. Engl. J. Med., 347, 111, 10.1056/NEJMra020552

Thoene, 1976, Intracellular cystine depletion by aminothiols in vitro and in vivo, J. Clin. Invest., 58, 180, 10.1172/JCI108448

Wilmer, 2011, Cysteamine restores glutathione redox status in cultured cystinotic proximal tubular epithelial cells, Biochim. Biophys. Acta, 1812, 643, 10.1016/j.bbadis.2011.02.010

Thoene, 2007, A review of the role of enhanced apoptosis in the pathophysiology of cystinosis, Mol. Genet. Metab., 92, 292, 10.1016/j.ymgme.2007.07.008

Gahl, 1987, Cysteamine therapy for children with nephropathic cystinosis, N. Engl. J. Med., 316, 971, 10.1056/NEJM198704163161602

Kimonis, 1995, Effects of early cysteamine therapy on thyroid function and growth in nephropathic cystinosis, J. Clin. Endocrinol. Metab., 80, 3257, 10.1210/jc.80.11.3257

Markello, 1993, Improved renal function in children with cystinosis treated with cysteamine, N. Engl. J. Med., 328, 1157, 10.1056/NEJM199304223281604

Gahl, 2007, Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy, Ann. Intern. Med., 147, 242, 10.7326/0003-4819-147-4-200708210-00006

Brodin-Sartorius, 2012, Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults, Kidney Int., 81, 179, 10.1038/ki.2011.277

Corden, 1981, Adverse reactions to oral cysteamine use in nephropathic cystinosis, Dev. Pharmacol. Ther., 3, 25, 10.1159/000457418

Dohil, 2003, The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine, J. Pediatr., 143, 224, 10.1067/S0022-3476(03)00281-6

Dohil, 2005, Esomeprazole therapy for gastric acid hypersecretion in children with cystinosis, Pediatr. Nephrol., 20, 1786, 10.1007/s00467-005-2027-1

Besouw, 2007, The origin of halitosis in cystinotic patients due to cysteamine treatment, Mol. Genet. Metab., 91, 228, 10.1016/j.ymgme.2007.04.002

Krischock, 2009, Drug-induced lupus and antiphospholipid syndrome associated with cysteamine therapy, Nephrol. Dial. Transplant., 24, 1997, 10.1093/ndt/gfp128

Ahmad, 2010, Cystinosis and lupus erythematosus: coincidence or causation, Pediatr. Nephrol., 25, 1543, 10.1007/s00467-010-1470-9

Rocha, 2011, New-onset lupus nephritis in a kidney transplant recipient with cystinosis – differential diagnosis with cysteamine-induced lupus: case report, Transplant. Proc., 43, 2265, 10.1016/j.transproceed.2011.05.009

Besouw, 2011, Cysteamine toxicity in patients with cystinosis, J. Pediatr., 159, 1004, 10.1016/j.jpeds.2011.05.057

Besouw, 2012, Copper deficiency in cystinosis patients, Pediatr. Nephrol., 27, 1634

Beckman, 1998, Developmental toxicity of cysteamine in the rat: effects on embryo-fetal development, Teratology, 58, 96, 10.1002/(SICI)1096-9926(199809/10)58:3/4<96::AID-TERA5>3.0.CO;2-7

Langman, 2012, Effectiveness on white blood cell cystine levels and comparison of safety, Clin. J. Am. Soc. Nephrol., 7, 1112, 10.2215/CJN.12321211

Schulte, 2011, The biological function of the Huntingtin protein and its relevance to Huntington's Disease pathology, Curr. Trends Neurol., 5, 65

Ross, 2011, Huntington's disease: from molecular pathogenesis to clinical treatment, Lancet Neurol., 10, 83, 10.1016/S1474-4422(10)70245-3

Shults, 1986, Huntington's disease: effect of cysteamine, a somatostatin-depleting agent, Neurology, 36, 1099, 10.1212/WNL.36.8.1099

Karpuj, 1999, Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei, Proc. Natl. Acad. Sci. U. S. A., 96, 7388, 10.1073/pnas.96.13.7388

Kahlem, 1996, Peptides containing glutamine repeats as substrates for transglutaminase-catalysed cross-linking: relevance to diseases of the nervous system, Proc. Natl. Acad. Sci. U. S. A., 93, 14580, 10.1073/pnas.93.25.14580

Munsie, 2011, Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease, Hum. Mol. Genet., 20, 1937, 10.1093/hmg/ddr075

Lorand, 1984, Transglutaminases, Mol. Cell. Biochem., 58, 9, 10.1007/BF00240602

Karpuj, 2002, Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine, Nat. Med., 8, 143, 10.1038/nm0202-143

Pinto, 2009, Measurement of sulfur-containing compounds involved in the metabolism and transport of cysteamine and cystamine. Regional differences in cerebral metabolism, J. Chromatogr. B, 877, 3434, 10.1016/j.jchromb.2009.05.041

Lesort, 2003, Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders, J. Biol. Chem., 278, 3825, 10.1074/jbc.M205812200

Revesz, 1965, Cysteamine-induced increase of cellular glutathione-level: a new hypothesis of the radioprotective mechanism, Nature, 207, 430, 10.1038/207430a0

Borrell-Pages, 2006, Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase, J. Clin. Invest., 116, 1410, 10.1172/JCI27607

Dubinsky, 2006, CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease, Mov. Disord., 21, 530, 10.1002/mds.20756

Schapira, 2011, Etiology and pathogenesis of Parkinson's disease, Mov. Disord., 26, 1049, 10.1002/mds.23732

Gibrat, 2011, Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases, Prog. Neuropsychopharmacol. Biol. Psychiatry, 35, 380, 10.1016/j.pnpbp.2010.11.023

Gibrat, 2010, Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor, Prog. Neuropsychopharmacol. Biol. Psychiatry, 34, 193, 10.1016/j.pnpbp.2009.11.005

Sun, 2010, Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice, Brain Res., 1335, 74, 10.1016/j.brainres.2010.03.079

Pillai, 2008, Cystamine prevents haloperidol-induced decrease of BDNF/TrkB signaling in mouse frontal cortex, J. Neurochem., 107, 941, 10.1111/j.1471-4159.2008.05665.x

Shieh, 2008, Potential antidepressant properties of cysteamine on hippocampal BDNF levels and behavioral despair in mice, Prog. Neuropsychopharmacol. Biol. Psychiatry, 32, 1590, 10.1016/j.pnpbp.2008.06.003

Tsai, 2006, Cysteamine-related agents could be potential antidepressants through increasing central BDNF levels, Med. Hypotheses, 67, 1185, 10.1016/j.mehy.2006.05.005

Cohen, 2011, Human fatty liver disease: old questions and new insights, Science, 332, 1519, 10.1126/science.1204265

Chalasani, 2012, The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association, Hepatology, 142, 1592

Dohil, 2011, Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease, Aliment. Pharmacol. Ther., 33, 1036, 10.1111/j.1365-2036.2011.04626.x

Dohil, 2012, The effect of cysteamine bitartrate on adiponectin multimerization in non-alcoholic fatty liver disease and healthy subjects, J. Pediatr., 161, 639, 10.1016/j.jpeds.2012.04.011

Min-Oo, 2007, Complex genetic control of susceptibility to malaria: positional cloning of the Char9 locus, J. Exp. Med., 204, 511, 10.1084/jem.20061252

Cavallini, 1968, Identification of pantethinase in horse kidney extract, FEBS Lett., 1, 119, 10.1016/0014-5793(68)80036-5

Min-Oo, 2010, Cysteamine, the natural metabolite of pantetheinase, shows specific activity against Plasmodium, Exp. Parasitol., 125, 315, 10.1016/j.exppara.2010.02.009

Min-Oo, 2010, Cysteamine, the molecule used to treat cystinosis, potentiates the antimalarial efficacy of artemisinin, Antimicrob. Agents Chemother., 54, 3262, 10.1128/AAC.01719-09

Brawer, 1994, The origin and composition of peroxidase-positive granules in cysteamine-treated astrocytes in culture, Brain Res., 633, 9, 10.1016/0006-8993(94)91516-4

Wan, 2011, Autophagy-mediated chemosensitization by cysteamine in cancer cells, Int. J. Cancer, 129, 1087, 10.1002/ijc.25771

Inano, 2000, Inhibitory effects of WR-2721 and cysteamine on tumor initiation in mammary glands of pregnant rats by radiation, Radiat. Res., 153, 68, 10.1667/0033-7587(2000)153[0068:IEOWAC]2.0.CO;2

Tatsuta, 1988, Inhibitory effect of prolonged administration of cysteamine on experimental carcinogenesis in rat stomach induced by N-methyl-N-nitro-N-nitrosoguanine, Int. J. Cancer, 41, 423, 10.1002/ijc.2910410318

Fujisawa, 2012, Cysteamine suppresses invasion, metastasis and prolongs survival by inhibiting matrix metalloproteinases in a mouse model of human pancreatic cancer, PLoS ONE, 7, e34437, 10.1371/journal.pone.0034437